This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Cardurion Pharmaceuticals, LLC, Janssen Pharmaceutica Nv. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Peng Zhou: Innovator in Pharmaceutical Chemistry
Introduction
Peng Zhou is a notable inventor based in Changzhou, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel crystalline forms of compounds that have therapeutic applications.
Latest Patents
Peng Zhou holds 2 patents that focus on innovative crystalline forms of specific chemical compounds. His latest patents include the monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one. This patent relates to crystalline polymorph forms that are essential for enhancing the efficacy of the compound. Another significant patent involves a crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate. This invention is particularly useful in the treatment of MALT-1 related diseases.
Career Highlights
Throughout his career, Peng Zhou has worked with prominent companies in the pharmaceutical industry. He has been associated with Cardurion Pharmaceuticals, LLC and Janssen Pharmaceutica NV, where he has contributed to various research and development projects.
Collaborations
Peng Zhou has collaborated with notable professionals in his field, including Haojuan Wei and Kristof Leonard Kimpe. These collaborations have further enriched his research and innovation efforts.
Conclusion
Peng Zhou is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable advancements in drug development. His innovative patents and collaborations highlight his commitment to improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
